Abstract
It is a well known and accepted fact that estrogens are the predominant hormone involved in human as well as rodent mammary cancer development and growth regulation. The possible physiological role of other hormones, particularly prolactin, in the etiology and progression of this disease is not as well established. However, the use of several rodent model systems has established that this lactogenic hormone plays an important role in the induction and progression of mammary tumors in experimental animals.
Chapter PDF
References
Yanai, R., and Nagasawa, H. Inhibition of mammary tumorigenesis by-ergot alkaloids and promotion of mammary tumorigenesis by pituitary isografts in adreno-ovariectomized mice. J. Natl. Cancer Inst., 48: 715–719, 1972.
Floss, H.G., Cassady, J.M., and Robbers, J.E. Influence of ergot alkaloids on pituitary prolactin and prolactin-dependent processes. J. Pharm. Sci., 62: 699–715, 1973.
Sinha, Y.N., Selby, F.W., and Vanderlaan, W.P. Effects of ergot drugs on prolactin and growth hormone secretion, and on mammary nucleic acid content in C3H/Bi mice. J. Natl. Cancer Inst., 52: 189–191, 1974.
Yanai, R., and Nagasawa, H. Effect of 2-Br-α-ergocryptine on pituitary synthesis and release of prolactin and growth hormone in rats. Hormone Res., 5: 1–5, 1974.
Yanai, R., and Nagasawa, H. Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-α-ergocryptine. J. Natl. Cancer Inst., 45: 1105–1112, 1970.
Welsch, C.W., and Morford, L.K. Influence of chronic treatment with 2-bromo-α-ergocryptine (CB-154) on the reproductive and lactational performance of the C3H/HeJ female mouse. Experientia, 30: 1353–1355, 1974.
Muhlbock, O., and Boot, L.M. Induction of mammary cancer in mice without the mammary tumor agent by isografts of hypophyses. Cancer Res., 19: 402–412, 1959.
Everett, J.W. Luteotrophic function of autografts of the rat hypophysis. Endocrinology, 54: 685–690, 1954.
Liebelt, A.G., and Liebelt, R.A. Effects of a single pituitaryisograft on mammary tumorigenesis in mice. Cancer Res., 21: 86–91, 1961.
Welsch, C.W., and Gribler, C. Prophylaxis of spontaneously developing mammary carcinoma in C3H/HeJ female mice by suppression of prolactin. Cancer Res., 33: 2939–2946, 1973.
Boot, L.M., Muhlbock, O., and Ropcke, G. Prolactin and the induction of mammary tumors in mice. Gen. Comp. Endocrinol., 2: 601–602, 1962.
Nandi, S., and McGrath, C.M. Mammary neoplasia in mice. Adv. Cancer Res., 17: 353–414, 1973.
Clifton, K.H., Yasukawa-Barnes, J., Tannaer, M.A., and Haning, R.V., Jr. Irradiation and prolatin effects on rat mammary carcinogenesis: intrasplenic pituitary and estrone capsule implants. J. Natl. Cancer Inst., 75: 167–175, 1985.
Welsch, C.W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res., 45: 3415–3443, 1985.
Welsch, C.W., Jenkins, T.W., and Meites, J. Increased incidence with mammary tumors in the female rat grafted with multiple pituitaries. Cancer Res., 30: 1024–1029, 1970.
Kwa, H.G., Vander Gugte, A.A., and Verhofstad, F. Radioimmunoassay of rat prolactin. Prolactin levels in plasma of rats with spontaneous pituitary tumors, primary oestrone-induced pituitary tumors or pituitary tumor transplants. Eur. J. Cancer, 5: 571–579, 1969.
Welsch, C.W., Nagasawa, H., and Meites, J. Increased incidence of spontaneous mammary tumors in female rats with induced hypothalamic lesions. Cancer Res., 30: 2310–2313, 1970.
Welsch, C.W., Squires, M.D., Cassells, E., Chen, C.L., and Meites, J. Median eminence lesions and serum prolactin: influence of ovariectomy and ergocornine. Am. J. Physiol., 221: 1714–1717, 1971.
Bishop, W., Fawcett, C.P., Krulich, L., and McCann, S.M. Acute and chronic effects hypothalamic lesions on the release of FSH, LH and prolactin in intact and castrated rats. Endocrinology, 91: 643–656, 1972.
Quadri, S.K., and Meites, J. Regression of spontaneous mammary tumors in rats by ergot drugs. Proc. Soc. Exp. Biol. Med., 138: 999– 1001, 1971.
Boyns, A.R., Buchan, R., Cole, E.N., Forrest, A.P.M., and Griffiths, K. Basal prolactin blood levels in three strains of rat with differing incidence of 7,12-dimethylbenzanthracene-induced mammary tumors. Eur. J. Cancer, 9: 169–171, 1973.
Cassell, E.E., Meites, J., and Welsch, C.W. Effects of ergocornine and ergocryptine on growth of 7,12-dimethylbenzanthracene-induced mammary tumors in rats. Cancer Res., 31: 1051–1053, 1971.
Butler, T.P., and Pearson, O.H. Regression of prolactin-dependent rat mammary carcinoma in response to antihormone treatment. Cancer Res., 31: 817–820, 1971.
Quadri, S.K., Clark, J.L., and Meites, J. Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats. Proc. Soc. Exp. Biol. Med., 142: 22–26, 1973.
Welsch, C.W., Iturri, G., and Meites, J. Comparative effects of hypophysectomy, ergocornine, and ergocornine-reserpine treatments on rat mammary carcinoma. Int. J. Cancer, 12: 206–212, 1973.
Chan, P., and Cohen, L.. Effect of dietary fat, antiestrogen and anti-prolactin on the development of mammary tumors in rats. J. Natl. Cancer Inst., 52: 25–30, 1974.
Dao, T.L., and Sunderland, H. Mammary carcinogenesis by 3-methyl-cholanthrene. I. Hormonal aspects in tumor induction and growth. J. Natl. Cancer Inst., 23: 567–585, 1959.
Kim, U., and Furth, J. Relation of mammary tumors to mammotropes. II. Hormone responsiveness of 3-methylcholanthrene induced mammary carcinomas. Proc. Soc. Exp. Biol. Med., 103: 643–645, 1960.
Pearson, O.H., Llerena, L., Molina, A., and Butler, T. Prolactin-dependent rat mammary cancer: a model for man? Trans. Assoc. Am. Physicians, 82: 225–238, 1969.
Welsch, C.W., and Meites, J. Effects of reserpine on development of 7,12-dimethylbenzanthracene-induced mammary tumors in female rats. Experientia, 26: 1133–1134, 1970.
Harada, Y. Pituitary role in the growth of metastasizing MRMT-1 mammary carcinoma in rats. Cancer Res., 36: 18–22, 1976.
Welsch, C.W., and Nagasawa, H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res., 37: 951–963, 1977.
Welsch, C.W., Clemens, J.A., and Meites, J. Effects of hypothalamic and amygdaloid lesions on development and growth of carcinogen- induced mammary tumors in the female rat. Cancer Res., 29: 1541–1549, 1969.
Nagasawa, H., and Yanai, R. Effects of prolactin or growth hormone on growth of carcinogen-induced mammary tumors of adeno-ovariectomized rats. Int. J. Cancer, 6: 488–495, 1970.
Welsch, C.W., and Rivera, E.M. Differential effects of estrogen and prolactin on DNA synthesis in organ cultures of DMBA-induced rat mammary carcinoma. Proc. Soc. Exp. Biol. Med., 139: 623–626, 1972.
Welsch, C.W., Calaf de Iturri, G., and Brennan, M.J. DNA synthesis of human, mouse, and rat mammary carcinomasin vitro: influence of insulin and prolactin. Cancer, 38: 1272–1281, 1976.
Welsch, C.W., Brown, C.K., Goodrich-Smith, M., Chiusano, J., and Moon, R.C. Synergistic effect of chronic prolactin suppression and retinoid treatment in the prophylaxis of N-methyl-N-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats. Cancer Res., 40: 3095–3098, 1980.
Arafah, B.M., Finegan, H.M., Roe, J., Manni, A., and Pearson, O.H. Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology, 111: 584–588, 1982.
Manni, A., and Wright, C. Polyamines as mediators of the effect of prolactin and growth hormone on the growth of N-nitrosomethylurea- induced rat mammary tumor culturedin vitroin soft agar. J. Natl. Cancer Inst., 74: 941–944, 1985.
MAnni, A., Pontari, M., and Wright, C. Autocrine stimulation by prolactin of hormone-responsive breast cancer growth in culture. Endocrinology, 117: 2040–2043, 1985.
Kwa, H.G., DeJong-Bakker, M., Engelsman, E., and Cleton, F.J. Plasmaprolactin in human breast cancer. Lancet, 1: 433–435, 1974.
Henderson, B.E., Gerkins, V., Rosario, I., Casagrande, J., and Pike, M.C. Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. N. Engl. J. Med., 293: 790–795, 1975.
Kwa, H.G., Clenton, F., DeJong-Bakker, M., Bulbrook, R.D., Hayward, J.L., and Wang, D.Y. Plasma prolactin and its relationship to risk factors in human breast cancer. Int. J. Cancer, 17: 441– 447, 1976.
Love, R.R., and Rose, D.P. Elevated bioactive prolactin in women at risk for familial breast cancer. Eur. J. Cancer Clin. Oncol., 21: 1553–1554, 1985.
Hill, P., Wynder, E.L., Kumar, H., Helman, P., Rona, G., and Kuno, K. Prolactin levels in populations at risk for breast cancer. Cancer Res., 36: 4102–4106, 1976.
Sheth, N.A., Ranadive, K.J., Suraiya, J.N., and Sheth, A.R. Circulating levels of prolactin in human breast cancer. Br. J. Cancer, 32: 160–167, 1975.
Cole, E.N., England, P.C., Sellwood, R.A., and Griffiths, K. Serumprolactin concentrations throughout the menstrual cycle of normal women and patients with recent breast cancer. Eur. J. Cancer, 13: 677–684, 1977.
Armstrong, B., Stevens, N., and Doll, R. Retrospective study of the association between use of Rauwolfia derivatives and breast cancer in English women. Lancet, 2: 672–675, 1974.
Heinonen, O.P., Shapiro, S., Tuominen, L., and Turunen, M.I. Reserpine use in relation to breast cancer. Lancet, 2: 675–677, 1974.
Jick, H., Slone, D., Shapiro, S., Heinonen, O.P., Hartz, S.C., Miettinen, O.S., Vessey, M.P., Lawson, D.H., and Miller, R.R. Reserpine and breast cancer. Lancet, 2: 669–671, 1974.
Landsdown, A.B.G. Prolactin secretion and mammary cancer. Trends Pharmacol. Sci., 4: 167–170, 1983.
Haltkamp, W., Nagel, G.A., Wander, H.E., Rauschecker, H.F., and von Heyden, D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J. Cancer, 34: 323–328, 1984.
Dugger, G.S., Van Wyk, J.F., and Newsome, J. Transection of the hypophyseal stalk in the management of metastatic mammary carcinoma. Am. Surg., 24: 603–608, 1958.
Murray, R.M.L., Mozaffarian, G., and Pearson, O.H. Prolactin levels with L-Dopa treatment in metastatic breast carcinoma. In: A.R. Boynes and K. Griffiths (eds.), Prolactin and Carcinogenesis, pp. 158–161. Cardiff, Wales: Alpha Omega Publishing, 1972.
Henson, J.C., Coune, A., and Staquet, M. Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancer. Eur. J. Cancer, 8: 155–156, 1972.
Schultz, K.D., Czygan, P.J., del Pozo, E., and Friesen, H.G. Varying response of human metastasizing breast cancer to the treatment with 2-Br-α-ergocryptine (CB-154). Case Report. In: C. Robyn and J.L. Pasteels (eds.), Human Prolactin, pp. 268–271. Amsterdam: Excerpta Medica, 1973.
Nagel, G.A., Holtkamp, W., Wander, H.E., and Blossey, H. Hyperprolactinemia and bromocriptine in metastatic breast cancer. Proc. Amer. Assoc. Cancer Res., 23: 126, 1982.
Peyrat, J.P., Vennin, P., Bonneterre, J., Hecquet, B., Vandewalle, B., Kelly, P.A., and Djiane, J. Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancer. Eur. J. Cancer Clin. Oncol., 20: 1363–1367, 1984.
Nicholson, R.I., Walker, K.J., Turkes, A., Dyas, J., Plowman, P.N., Williams, M., and Blarney, R.W. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J. Steroid Biochem., 23: 843–847, 1985.
Klijn, J.G.M., de Jong, F.H., Lamberts, S.W.J., and Blankenstein, M.A. LHRH-agonist treatment in clinical and experimental human breast cancer. J. Steroid Biochem., 23: 867–873, 1985.
Holdaway, I.M., and Friesen, H.G. Hormone binding by human mammary carcinoma. Cancer Res., 37: 1946–1952, 1977.
Partridge, R.K., and Hahnel, R. Prolactin receptors in human breast carcinoma. Cancer, 43: 643–646, 1979.
Peyrat, J.P., DeWailly, D., Djiane, J., Kelly, P.A., Vandewalle, B., Bonneterre, J., and Lefebvre, J. Total prolactin binding sites in human breast cancer biopsies. Breast Cancer Res. Treat., 1: 369–373, 1981.
Rai-Venter, B., Nemoto, T., Schneider, S.L., and Dao, T.L. Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age. Breast Cancer Res. Treat., 1: 233–243, 1981.
Codegone, M.L., DiCarlo, R., Muccioli, G., and Bussolati, G. Histology and cytometrics in human breast cancers assayed for the presence of prolactin receptors. Tumori, 67: 549–552, 1981.
Turcot-Lemay, L., and Kelly, P.A. Prolactin receptors in human breast tumors, J. Natl. Cancer Inst., 68: 381–383, 1982.
Bonneterre, J., Peyrat, J.P., Vandewalle, B., Beuscart, R., Vie, M.C., and Cappelaere, P. Prolactin receptors in human breast cancer. Eur. J. Cancer Clin. Oncol., 18: 1157–1162, 1982.
Calandra, R.S., Charreau, E.H., Royer-de-Giaroli, M., and Baldi, A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. In: E. Gurpide, R. Calandra, C. Levy, and R.J. Soto (eds.), Hormones and Cancer, pp. 97–108. New York: Alan R. Liss, Inc., 1984.
Marchetti, E., Rimondi, A.P., Querzoli, P., Fabris, G., and Nenci, I. Prolactin and prolactin binding sites in human breast cancer cells. In: E. Gurpide, R. Calandra, C. Levy, and R.J. Soto (eds.), Hormones and Cancer, pp. 109–117. New York: Alan R. Liss, Inc., 1984.
Peyrat, J.P., Djiane, J., Kelly, P.A., Vandewalle, B., Bonneterre, J., and Demaille, A. Characterization of prolactin receptors in human breast cancer. Breast Cancer Res. Treat., 4: 275–281, 1984.
L’Hermite-Baleriaux, M., Casteels, S., Vokaer, A., Loriaus, C., Noel, G., and L’Hermite, M. Prolactin and prolactin receptors in human breast disease. Prog. Cancer Res. Therapy, 31: 325–334, 1984.
Dhadly, M.S., and Walker, R.A. The localization of prolactin binding sites in human breast tissue. Int. J. Cancer, 31: 433–437, 1983.
McManus, M.J., and Welsch, C.W. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer, 54: 1920–1927, 1984.
Kleejer-Anderson, P., and Buehring, G. Effects of hormones on growth rates of malignant and non-malignant human mammary epithelia in cell culture. In Vitro. 16: 491–501, 1980.
Malarkey, W.B., Kennedy, M., Allred, L.E., and Milo, G. Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J. Clin. Endocrinol. Metab., 56: 673–677, 1983.
Welsch, C.W., and McManus, M.J. Stimulation of DNA synthesis by human placental lactogen or insulin in organ cultures of benign human breast tumors. Cancer Res., 37: 2257–2261, 1977.
Welsch, C.W., Dombroske, S.E., McManus, M.J., and Calaf, G. Effect of human, bovine and ovine prolactin on DNA synthesis by organ cultures of benign human breast tumors. Br. J. Cancer, 40: 866–871, 1979.
Hammond, S.L., Ham, R.G., and Stampfer, M.R. Serum-free growth of human mammary epithelial cells: rapid colonal growth in defined medium and extended serial passage with pituitary extract. Proc. Natl. Acad. Sci. USA, 81: 5435–5439, 1984.
Manni, A,, Wright, C., Davis, Glenn, J., Joehl, R., and Feil, P. Promotion by prolactin of the growth of human breast neoplasms culturedin vitroin the soft agar clonogenic assay. Cancer Res., 46: 1669–1672, 1986.
Leung, C.K.H., and Shiu, R.P.C. Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice. Cancer Res., 41: 546–551, 1981.
Welsch, C.W., Swim, E.L., McManus, M.J., White, A.C., and McGrath, C.M. Estrogen induced growth of human breast cancer cells (MCF-7) in athymic nude mice is enhanced by secretions from a transplantable pituitary tumor. Cancer Lett., 14: 309–316, 1981.
Shafie, S.M., and Grantham, F.H. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J. Natl. Cancer. Inst., 67: 51–56, 1981.
Shiu, R.P.C. Prolactin receptors in human breast cancer cells in long-term tissue culture. Cancer Res., 39: 4381–4386, 1979.
Shiu, R.P.C. Prolactin, pituitary hormones, and breast cancer. In: M.C. Pike, P.K. Siiteri, and C.W. Welsch (eds.), Hormones and Breast Cancer: Banbury Report No. 8, pp. 185–196. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1981.
Murphy, L.J., Vrhovsek, E., McGinley, R., Murphy, L.C., Sutherland, R.L., and Lazarus, L. Growth hormone receptors in human breast cancer: correlation with oestrogen receptor status. Prog. Cancer Res. Therapy, 31: 313–320, 1984.
Simon, W.E., Pahnke, V.G., and Holzel, F.In vitromodulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. J. Clin. Endocrinol. Metab., 60: 1243–1249, 1985.
Biswas, R., and Vonderhaar, B.K. Tamoxifen inhibition of growth and binding activity of lactogenic hormones in prolactin-responsive MCF-7 human breast cancer and Nb2 rat lymphoma cells. Prov. Int. Assoc. Breast Cancer Res., p. 68, 1985.
Murphy, L.J., Sutherland, R.L., and Lazarus, L. Regulation of growth hormone and epidermal growth factor receptors by progestins in breast cancer cells. Biochem. Biophys. Res. Commun., 131: 767–773, 1985.
Murphy, L.J., Murphy, L.C., Stead, B., Sutherland, R.L., and Lazarus, L. Modulation of Lactogenic receptors by progestins in cultured human breast cancer cells. J. Clin. Endocrinol. Metab., 62: 280–287, 1986.
Shiu, R.P.C., and Paterson, J.A. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T47D) by human prolactin and growth hormone. Cancer Res., 44: 1178–1186, 1984.
Leung, B.S., Potter, A.H., and Qurishi, S. Interaction of prolactin, estrogen and progesterone in a human mammary carcinoma cell line, CAMA-1. I. Cell growth and thymidine uptake. J. Steroid Biochem., 15: 421–427, 1981.
Shafie, S., and Brooks, S.C. Effect of prolactin on growth and the estrogen receptor level of human breast cancer cells (MCF-7). Cancer Res., 37: 792–799, 1977.
Jozan, S., Tournier, J.F., Tauber, J.P., and Bayard, F. Adaptation of the human breast cancer cell line MCF-7 to serum-free medium culture on extracellular matrix. Biochem. Biophys. Res. Commun., 107: 1566–1570, 1982.
Biswas, R., and Vonderhaar, B.K. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Submitted, 1986.
Djiane, J., Houdebine, L.M., and Kelly, P.A. Down-regulation of prolactin receptors in rabbit mammary gland: differential subcellular localization. Proc. Soc. Exp. Biol. Med., 168: 378–381, 1981.
Gertler, A., Shamay, A., Cohen, N., Ashkenzai, A., Friesen, H.G., Levanon, A., Gorecki, M., Aviv, H., Hadary, D., and Vogel, T. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a nobel form of a modified recombinant hGH. Endocrinology, 118: 720–726, 1986.
Shiu, R.P.C., and Iwasiow, B.M. Prolactin-inducible proteins in human breast cancer cells. J. Biol. Chem., 260: 11307–11313, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Vonderhaar, B.K., Biswas, R. (1987). Prolactin Effects and Regulation of its Receptors in Human Mammary Tumor Cells. In: Medina, D., Kidwell, W., Heppner, G., Anderson, E. (eds) Cellular and Molecular Biology of Mammary Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0943-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0943-7_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-42761-9
Online ISBN: 978-1-4613-0943-7
eBook Packages: Springer Book Archive